Alzheimer Disease Clinical Trial
— ExCiTE-AOfficial title:
Effect of Exercise Training on Biochemical and Gait/Balance Parameters in Alzheimer's Patients
Verified date | June 2019 |
Source | University of Genova |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The objective of this study was to examine the effects of exercise training on physical function and biochemical markers in elderly Alzheimer's disease patients.
Status | Completed |
Enrollment | 20 |
Est. completion date | November 15, 2017 |
Est. primary completion date | July 1, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 80 Years to 90 Years |
Eligibility |
Inclusion Criteria: - Subjects with official diagnosis of Alzheimer's disease; - Subjects with MMSE higher than12. Exclusion Criteria: • Subjects with MMSE below 12 (indicating severe dementia and impairment). |
Country | Name | City | State |
---|---|---|---|
Italy | University of Genova | Genoa |
Lead Sponsor | Collaborator |
---|---|
University of Genova |
Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Tinetti test | The 3-likert test assesses balance and gait abilities with an individual sitting in an armless chair, rising up, staying standing, turning 360° and then sitting back down. Gait is scored over 12 and balance is scored over 16, totalling 28 points. | Approximately 10-15 minutes | |
Primary | Berg Balance Scale | The 14-item 5-likert (from 0 to 4) scale objectively determines a patient's balance ability during a series of predetermined tasks. Scores of each item are summed up: the total score ranges from 0 to 56. The lowest the score the lowest is the level of function, the highest the score the highest is the level of function. | Approximately 20 minutes | |
Primary | 6-minute walking test | This test is a sub-maximal exercise used to evaluate aerobic capacity and endurance. | 6 minutes | |
Primary | Timed up and go test | The test measures abilities of a patient initially in a seated position The patient is then asked to stand up up, walk 3 meters, turn around, walk back to the chair and sit down. | Approximately 14 seconds | |
Primary | "Walking While Talking" test | This test is a dual-task test, consisting in walking while reciting the alphabet or alternate letters of the alphabet. | Approximately 1 minute | |
Primary | Red blood cell count | Assessed with routine blood/biochemical assays | Approximately 10-15 minutes | |
Primary | White blood cell count | Assessed with routine blood/biochemical assays | Approximately 10-15 minutes | |
Primary | Hemoglobin | Assessed with routine blood/biochemical assays | Approximately 10-15 minutes | |
Primary | Platelet count | Assessed with routine blood/biochemical assays | Approximately 10-15 minutes | |
Primary | Hematocrit | Assessed with routine blood/biochemical assays | Approximately 10-15 minutes | |
Primary | Triglycerides | Assessed with routine blood/biochemical assays | Approximately 10-15 minutes | |
Primary | Cholesterol | Assessed with routine blood/biochemical assays | Approximately 10-15 minutes | |
Primary | Total bilirubin | Assessed with routine blood/biochemical assays | Approximately 10-15 minutes | |
Primary | AST (aspartate aminotransferase) | Assessed with routine blood/biochemical assays | Approximately 10-15 minutes | |
Primary | ALT (alanine aminotransferase) | Assessed with routine blood/biochemical assays | Approximately 10-15 minutes | |
Primary | Blood pressure | Assessed with routine blood/biochemical assays | Approximately 10-15 minutes | |
Primary | Creatinine | Assessed with routine blood/biochemical assays | Approximately 10-15 minutes | |
Primary | Urea | Assessed with routine blood/biochemical assays | Approximately 10-15 minutes | |
Primary | Glucose | Assessed with routine blood/biochemical assays | Approximately 10-15 minutes | |
Primary | Sodium | Assessed with routine blood/biochemical assays | Approximately 10-15 minutes | |
Primary | Calcium | Assessed with routine blood/biochemical assays | Approximately 10-15 minutes | |
Primary | Potassium | Assessed with routine blood/biochemical assays | Approximately 10-15 minutes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04044495 -
Sleep, Rhythms and Risk of Alzheimer's Disease
|
N/A | |
Completed |
NCT04079803 -
PTI-125 for Mild-to-moderate Alzheimer's Disease Patients
|
Phase 2 | |
Terminated |
NCT03052712 -
Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies
|
N/A | |
Recruiting |
NCT04520698 -
Utilizing Palliative Leaders In Facilities to Transform Care for Alzheimer's Disease
|
N/A | |
Active, not recruiting |
NCT04606420 -
Can Lifestyle Changes Reverse Early-Stage Alzheimer's Disease
|
N/A | |
Recruiting |
NCT05820919 -
Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase
|
N/A | |
Terminated |
NCT03672474 -
REGEnLIFE RGn530 - Feasibility Pilot
|
N/A | |
Completed |
NCT03430648 -
Is Tau Protein Linked to Mobility Function?
|
||
Recruiting |
NCT05557409 -
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation
|
Phase 3 | |
Recruiting |
NCT04949750 -
Efficacy of Paper-based Cognitive Training in Vietnamese Patients With Early Alzheimer's Disease
|
N/A | |
Recruiting |
NCT04522739 -
Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease
|
Phase 4 | |
Recruiting |
NCT05288842 -
Tanycytes in Alzheimer's Disease and Frontotemporal Dementia
|
||
Completed |
NCT06194552 -
A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07
|
Phase 1 | |
Completed |
NCT03239561 -
Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants
|
Early Phase 1 | |
Completed |
NCT03184467 -
Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03676881 -
Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
|
||
Terminated |
NCT03487380 -
Taxonomic and Functional Composition of the Intestinal Microbiome: a Predictor of Rapid Cognitive Decline in Patients With Alzheimer's Disease
|
N/A | |
Completed |
NCT05538455 -
Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases
|
N/A | |
Recruiting |
NCT05328115 -
A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease
|
Phase 1 | |
Completed |
NCT05562583 -
SAGE-LEAF: Reducing Burden in Alzheimer's Disease Caregivers Through Positive Emotion Regulation and Virtual Support
|
N/A |